CD274 and gastric cancer: In 2017, the United States Food and Drug Administration (FDA) granted accelerated approval of the programmed death receptor-1 (PD-1) inhibitor pembrolizumab for refractory PD-L1-positive gastric cancers [12], although the approval was withdrawn in 2021 [13].